AGENDA

Optimizing Sequencing Strategies in mCRPC July 22, 2021 5:00 PM ET



Introduction

Neal Shore, MD 3 minutes

The Role of Cabazitaxel

William Oh, MD 10 minutes

The Role of Sipuleucel-T

Cathy Marshall, MD 10 minutes

The Role of Radium-223

Joe O'Sullivan, MD 10 minutes

The Role of Olaparib

Joaquin Matteo, MD 10 minutes

The Role of Rucaparib

Wassim Abida, MD 10 minutes

The Role of Lutetium

Michael Morris, MD 10 minutes

Conclusion

Neal Shore, MD 2 minutes

Description:

With the rapid and robust development of novel therapeutics for advanced prostate cancer, urologists, medical oncologists, and radiation oncologists are regularly challenged to understand the variables associated with the optimization for sequencing approved prostate cancer therapeutic agents. Clinicians require ongoing education in order to assess the information required for optimal sequencing of approved advanced prostate cancer treatments. This program will address educational gaps in practice by improving knowledge and the application to adequately sequence therapeutic options and treatment selection in order to provide personalized sequencing of therapeutics for patients with prostate cancer.

Desired outcome:

As a result of this program urologists will be able to implement and evaluate sequencing of therapeutic options for patients with prostate cancer.

Learning objectives:

At the conclusion of this activity participants will be able to:

Distinguish sequencing of therapeutic options for metastatic castration resistant prostate cancer

Evaluate sequencing agents to personalize treatment for patients with prostate cancer

References:

Therapeutic Patterns and Barriers to the Treatment of Advanced Prostate Cancer: A Survey of Academic and Community Urologists in the United States
Edouard J. Trabulsi, Patricia Jassak. Hong Tang, Sharon Hwang, and Gregory D. Salinas
https://doi.org/10.1016/j.urpr.2016.11.008